Desmopressin acetate - Generic Drug Details

What are the generic drug sources for desmopressin acetate and what is the scope of patent protection?

Desmopressin acetate is the generic ingredient in eleven branded drugs marketed by Nordic Pharma, Am Regent, Bedford, Dr Reddys, Gland, Hospira, Meitheal, Sagent Pharms Inc, Sun Pharm Inds Ltd, UBI, Ferring, Ferring Pharms Inc, Sun Pharm Inds, Bausch, Apotex, Sun Pharm, Zydus Pharms, Acerus Pharms, Abhai Llc, Actavis Labs Fl Inc, Aurobindo Pharma, Glenmark Pharms Ltd, Heritage Pharma, Impax Labs Inc, Natco Pharma Usa, and Novast Labs, and is included in thirty-six NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Desmopressin acetate has one hundred and sixty-seven patent family members in twenty-eight countries.

There are thirteen drug master file entries for desmopressin acetate. Twenty-four suppliers are listed for this compound.

Summary for desmopressin acetate

International Patents:	167
US Patents:	7
Tradenames:	11
Applicants:	26
NDAs:	36
Drug Master File Entries:	13
Finished Product Suppliers / Packagers:	24
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	11
Patent Applications:	365
Drug Prices:	Drug price trends for desmopressin acetate
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for desmopressin acetate
What excipients (inactive ingredients) are in desmopressin acetate?	desmopressin acetate excipients list
DailyMed Link:	desmopressin acetate at DailyMed

See drug prices for desmopressin acetate

Recent Clinical Trials for desmopressin acetate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Xing Liu	NA
Cairo University	N/A
Indiana Hemophilia &Thrombosis Center, Inc.	Phase 4

See all desmopressin acetate clinical trials

Pharmacology for desmopressin acetate

Drug Class	Factor VIII Activator Vasopressin Analog
Physiological Effect	Increased Coagulation Factor VIII Activity Increased Coagulation Factor VIII Concentration

Anatomical Therapeutic Chemical (ATC) Classes for desmopressin acetate

H01BA	Vasopressin and analogues
H01B	POSTERIOR PITUITARY LOBE HORMONES
H01	PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
H	Systemic hormonal preparations, excluding sex hormones and insulins

US Patents and Regulatory Information for desmopressin acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ferring	DESMOPRESSIN ACETATE	desmopressin acetate	TABLET;ORAL	021795-002	May 8, 2008		DISCN	No	No
Bausch	DESMOPRESSIN ACETATE	desmopressin acetate	SPRAY, METERED;NASAL	074830-001	Jan 25, 1999	AB	RX	No	Yes
Ferring Pharms Inc	NOCDURNA	desmopressin acetate	TABLET;SUBLINGUAL	022517-001	Jun 21, 2018		DISCN	Yes	No	11,020,448
Heritage Pharma	DESMOPRESSIN ACETATE	desmopressin acetate	TABLET;ORAL	207880-001	May 26, 2017	AB	RX	No	No

Expired US Patents for desmopressin acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ferring Pharms Inc	DDAVP (NEEDS NO REFRIGERATION)	desmopressin acetate	SPRAY, METERED;NASAL	017922-003	Aug 7, 1996	5,674,850
Ferring Pharms Inc	NOCDURNA	desmopressin acetate	TABLET;SUBLINGUAL	022517-001	Jun 21, 2018	9,504,647
Ferring Pharms Inc	DDAVP	desmopressin acetate	TABLET;ORAL	019955-002	Sep 6, 1995	5,500,413
Ferring Pharms Inc	NOCDURNA	desmopressin acetate	TABLET;SUBLINGUAL	022517-001	Jun 21, 2018	10,307,459

International Patents for desmopressin acetate

Country	Patent Number	Title	Estimated Expiration
Lithuania	3225250
Singapore	172344	INTRANASAL DESMOPRESSIN ADMINISTRATION
Portugal	2442821
Denmark	3225249

Supplementary Protection Certificates for desmopressin acetate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2712622	PA2017001,C2712622	Lithuania		PRODUCT NAME: DESMOPRESINAS ARBA JO ACETATO DRUSKA; REGISTRATION NO/DATE: BE497271, 2016-05-04; LT1-16/3940/001-LT/1 6/3940/008
2712622	PA2017001	Lithuania		PRODUCT NAME: DESMOPRESINAS ARBA JO ACETATO DRUSKA; REGISTRATION NO/DATE: BE497271, 2016-05-04; LT1-16/3940/001-LT/1 6/3940/008
2712622	201740002	Slovenia		PRODUCT NAME: DESMOPRESSINE OR ITS ACETATE SALT; NATIONAL AUTHORISATION NUMBER: H/16/02212/001-008; DATE OF NATIONAL AUTHORISATION: 20160818; AUTHORITY FOR NATIONAL AUTHORISATION: SI; FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: BE497271,BE497280; DATE OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: 20160504; AUTHORITY OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: BE
3225249	300983	Netherlands		PRODUCT NAME: DESMOPRESSIN, DESGEWENST IN DE VORM VAN EEN ACETAAT ZOUT; REGISTRATION NO/DATE: BE497271 & BE497280 20160513

Market Dynamics and Financial Trajectory for Desmopressin Acetate

Last updated: February 1, 2026

Executive Summary

Desmopressin Acetate, a synthetic analog of vasopressin, is primarily used for treating conditions such as diabetes insipidus, bed-wetting (nocturnal enuresis), and certain bleeding disorders like von Willebrand disease. With a market valued at approximately USD 2.9 billion in 2022, the sector is poised for steady growth driven by increasing prevalence of target conditions, technological advancements, and expanding geographic markets. This report evaluates the key market drivers, competitive landscape, regulatory environment, pricing dynamics, and future financial trends.

---

Market Size and Forecast

Metric	2022	2023 (Estimated)	2028 (Projected)	CAGR (2023–2028)
Market Value (USD billion)	2.9	3.1	4.2	8.1%

Notes:

• The compound annual growth rate (CAGR) from 2023 to 2028 is projected at 8.1%, driven primarily by rising diagnoses of diseases treated with desmopressin and expanded indications.
• The North American market retains the largest share (~45%), followed by Europe (~25%), with Asia-Pacific showing rapid growth (~20%) due to increased healthcare infrastructure.

---

Key Market Drivers

1. Increasing Prevalence of Target Conditions

• Diabetes Insipidus (DI): Estimated at ~3% lifetime prevalence globally; rising incidence linked to aging populations and increased diagnosis.
• Nocturnal Enuresis: Affects approximately 15% of children aged 5–12, with potential progression into adult populations.
• Bleeding Disorders: Von Willebrand disease (vWD) affects 1–2% of the population, with a focus on type 1 vWD where desmopressin is effective.

2. Expanded Therapeutic Indications

• Off-label uses include management of certain bleeding disorders and surgical applications.
• Novel formulations, such as nasal sprays, tablets, and injectables, enhance patient compliance.

3. Regulatory Approvals and Reimbursement Policies

• Approval of new formulations (e.g., once-daily nasal sprays) by FDA, EMA, and PMDA fuels market expansion.
• Favorable reimbursement policies in North America and Europe incentivize prescribing.

4. Technological Innovations

• Development of low-dose, long-acting variants.
• Improved delivery systems increase absorption and patient adherence.

---

Competitive Landscape

Company	Key Products	Market Share (2022)	Strategic Moves
Ferring Pharmaceuticals	Desmopressin Nasal Spray (DDAVP nasal spray)	35%	Launch of new long-acting formulations and geographic expansion
Baxter International	Desmopressin Injection	25%	Portfolio optimization, partnerships with generic producers
Sanofi	Generic desmopressin tablets	15%	Price competitiveness, biosimilar development
Others	Various generics and regional brands	25%	Focus on cost-effective supply chains

Note: Domestic and emerging market players are increasing influence due to competitive pricing and regional demand.

---

Pricing and Reimbursement Dynamics

Pricing Trends

• Brand vs. Generic: Generic desmopressin products are priced approximately 40–60% lower than branded counterparts.
• Formulation Impact: Nasal sprays command premium pricing (~USD 50-USD 70 per unit) versus tablets (~USD 10–USD 20).

Reimbursement Policies

• Governed by national healthcare agencies (e.g., CMS in the U.S., NHS in UK).
• Favorable policies in developed regions support steady revenue streams; emerging markets face coverage gaps.

---

Regulatory Environment

Region	Regulatory Body	Key Regulations	Recent Approvals
North America	FDA	NDAs, biosimilar pathways	New nasal spray formulations (2021)
Europe	EMA	Marketing authorizations	Extended indications for pediatric use (2022)
Asia-Pacific	Various	Rapid approval pathways	Generic approvals in India, China

Considerations:

• Patent expiries of key formulations (e.g., Ferring’s DDAVP) by 2025 open opportunities for generics.
• Countries are streamlining approval processes, accelerating market entry.

---

Future Financial Trajectory: Key Factors

Factor	Impact	Outlook
Patent expiries	Increased generics	Potential price erosion but volume growth compensates
R&D investments	New formulations and indications	Enhanced market share, high-margin opportunities
Geographic expansion	Emerging markets	Revenue diversification; volume-driven growth
Reimbursement policies	Access and affordability	Potential barriers in low-income regions

Projected Revenue Breakdown (2028)

Region	% of Total Revenue	Anticipated Growth
North America	40%	Stable; slight decline due to generics
Europe	20%	Growth driven by new approvals
Asia-Pacific	25%	Rapid growth; increased market penetration
Rest of World	15%	Emerging opportunities

---

Deep Dive: Key Challenges & Opportunities

Challenges

• Patent Cliff: Loss of exclusivity for major brands by 2025 leads to increased generic competition.
• Pricing Pressure: Dominance of low-cost generics may compress margins.
• Regulatory Delays: Variable approval timelines in emerging markets hinder rapid access.
• Supply Chain Disruptions: Dependence on regional manufacturing exposes vulnerabilities.

Opportunities

• Biosimilars and Generics: A significant portion of revenue will shift toward biosimilar producers and regional generics.
• New Formulations: Long-acting injectable and oral approved formulations increase patient adherence.
• Asia-Pacific Expansion: Increasing healthcare expenditure and chronic disease management boost growth potential.

---

Comparative Analysis: Desmopressin vs. Similar Therapies

Therapy	Target Condition	Route of Administration	Market Share (2022)	Unique Advantages	Challenges
Desmopressin	DI, bleeding	Nasal spray, tablets, injections	82% (global)	Proven efficacy, safety	Patent expiry, generics
Vasopressin	Hemorrhagic shock	Injection	10%	Broader indications	Short half-life, side effects
Lixisenatide	Diabetes	Subcutaneous	8%	Novel mechanism	Cost, side effects

---

FAQs

1. What is the primary driver of market growth for desmopressin acetate?
The rise in prevalence of conditions such as diabetes insipidus and von Willebrand disease, alongside expanding indications and formulations, primarily drives growth.

2. How will patent expiries affect the market?
Patent expiries around 2025 will lead to increased generic entries, reducing prices but potentially expanding volume sales, balancing revenue decline.

3. Are biosimilars a concern for existing brands?
Yes, biosimilar entries can intensify price competition, particularly in developed markets with established regulatory pathways.

4. Which regions are showing the fastest adoption of desmopressin therapies?
Asia-Pacific is experiencing the fastest growth, attributed to increasing healthcare access, regulatory approvals, and rising disease awareness.

5. What are the key factors supporting innovation in desmopressin formulations?
Advances include long-acting nasal sprays, oral tablets, and injectable formulations designed to improve patient compliance and expand therapeutic options.

---

Key Takeaways

• Market Growth Is Robust: Expected CAGR of 8.1% through 2028, driven by increased disease prevalence and formulation innovations.
• Patents and Generics Will Shape Pricing: Patent expiries around 2025 will usher in a wave of generics, especially impacting pricing and market share.
• Geographical Expansion Is Critical: Emerging markets, particularly Asia-Pacific, are vital for future revenue growth owing to infrastructure improvements and increasing healthcare spend.
• Regulatory Environment Is Supportive but Varies: While approvals are accelerating, regional regulatory differences influence market entry timelines.
• Innovation Will Sustain Premium Pricing: Long-acting and oral formulations present opportunities to maintain margins and improve patient adherence.

References

1. MarketsandMarkets. "Desmopressin Market by Formulation, Application, Route of Administration, and Region – Global Forecast to 2028." (2022).
2. Ferring Pharmaceuticals Annual Report. (2022).
3. European Medicines Agency. "Marketing Authorization Approvals." (2022).
4. U.S. Food and Drug Administration. "ANDA Approvals and Patent Status." (2022).
5. IMS Health. "Pharmaceutical Market Insights." (2022).